Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

NCT03334617 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

528

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Durvalumab
DRUG: Danvatirsen
DRUG: Ceralasertib
DRUG: Vistusertib
DRUG: Olaparib
DRUG: Oleclumab
DRUG: Trastuzumab deruxtecan
DRUG: Cediranib

Sponsor

AstraZeneca